The Canadian subsidiary will focus primarily on therapeutic solutions for respiratory and skin diseases .
According to the CEO of Almirall Canada, Ed Dybka : " We are at a very important moment for Almirall , advances in research projects , key regulatory milestones and new partnerships will be the foundation for a sustained period of international growth , where we have an important role and underlines our commitment to the U.S. pharmaceutical market . "
Headquartered in Mississauga , the new subsidiary will support the launch of new products in the local market Almirall , including an innovative new treatment for chronic obstructive pulmonary disease (COPD ) : Tudorza ® Genuair ® , which is marketed in the fall.
Almirall fourteenth Canada is the subsidiary of the pharmaceutical company joins existing in Europe and Mexico .
Considering the milestones achieved by Almirall in Europe throughout its history, the General Manager of Almirall Canada has stated : "We want to stand out for being a pharmaceutical company in which they can develop new lines of business as well as continue our commitment to collaborate with the medical community to improve the quality of life of Canadian patients , "said Dybka .
Research and development
Research has been a fundamental part to create , for more than 40 years , the DNA of Almirall . In 2012 , Almirall reinvested more than 23% of its sales in R & D - an increase of 10 % over the previous year . This was the largest investment in research and development in the Spanish pharmaceutical sector and the third in the ranking of all companies.
In late 2012 , 20% of all staff of the company is dedicated to R & D. In total, more than 500 people , including scientists and experts play an essential role in all stages of research and product development for applications for marketing authorization record .
Almirall , corporate values reflect our attitude : how we work and how we interact daily professional and personal level , both within and outside our organization.
Our four core values : trust , innovation , teamwork and personal leadership , define the company and help us to improve our performance and create value . The results of the company are the sum of individual efforts dedicated to the fulfillment of our vision , objectives and goals.
Almirall is a pharmaceutical company committed to providing valuable drugs through its efforts in R & D , which exceeded 23% of its sales in 2012 , along with external agreements , licenses and collaborations. Through the search for innovative medicines, we aim to become a leading company in the areas of respiratory disease and dermatology , with a high interest in gastrointestinal and pain. With more than 3,000 employees in 22 countries , Almirall has generated total revenues of 900 million euros in 2012 .
The company was founded in 1943 and its headquarters are located in Barcelona ( Spain ) . Almirall shares traded on the Spanish Stock Exchange ( ticker : ALM ) .
For more information, visit the website: www.almirall.com